{"schema_version":"1.0","type":"article","title":"FDA adds a vision-loss warning to every GLP-1","url":"https://drugnews.com.tw/articles/2026-11-14-glp1-naion-vision-warning-fda-classwide-mounjaro-taiwan-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-14-glp1-naion-vision-warning-fda-classwide-mounjaro-taiwan-en.md","lang":"en","date":"2026-11-14","publish_at":"2026-11-14T08:00:00+08:00","updated_at":"2026-11-14","category":"商業分析系列","topic":"商業分析系列","tags":["GLP-1","NAION","drug safety","Mounjaro","Taiwan FDA"],"summary":"On Nov 9 FDA required NAION warnings on all GLP-1 labels, including Mounjaro and the Foundayo pill. Taiwan had labeled only semaglutide and began a class review on Nov 10. We unpack the 1.7x ratio, the lawsuits and Taiwan's next step.","key_points":["On November 9, 2026, FDA required all GLP-1 drugs to add NAION to the Warnings and Precautions section, covering semaglutide, tirzepatide and oral orforglipron.","FDA's 126-trial meta-analysis found 15 probable cases, 6.4 versus 3.8 per 100,000 person-years; versus SGLT-2 inhibitors in real-world data the hazard ratio was 1.19, not significant.","Taiwan's FDA required NAION labeling only for semaglutide in June 2026 and announced a class-wide safety re-evaluation on November 10."],"facts":[{"claim":"FDA required class-wide NAION labeling for GLP-1 RAs","value":"2026-11-09","unit":"date","as_of":"2026-11-09","source":"FDA DSC"},{"claim":"GLP-1 RA NAION incidence in RCT meta-analysis","value":6.4,"unit":"per 100,000 PY","as_of":"2026-11-09","source":"FDA DSC"},{"claim":"Comparator NAION incidence in RCT meta-analysis","value":3.8,"unit":"per 100,000 PY","as_of":"2026-11-09","source":"FDA DSC"},{"claim":"RCTs in FDA meta-analysis","value":126,"unit":"trials","as_of":"2026-11-09","source":"FDA DSC"},{"claim":"Participants in FDA meta-analysis","value":134253,"unit":"patients","as_of":"2026-11-09","source":"Pharmacy Times"},{"claim":"Probable NAION events in meta-analysis (10 GLP-1, 5 placebo)","value":15,"unit":"events","as_of":"2026-11-09","source":"Pharmacy Times"},{"claim":"Sentinel HR GLP-1 vs SGLT-2 (95% CI 0.91-1.54)","value":1.19,"unit":"HR","as_of":"2026-11-09","source":"FDA DSC"},{"claim":"Sentinel HR GLP-1 vs DPP-4 (95% CI 1.02-2.01)","value":1.43,"unit":"HR","as_of":"2026-11-09","source":"FDA DSC"},{"claim":"Sentinel incidence GLP-1 / SGLT-2 / DPP-4","value":"30-32 / 31 / 26","unit":"per 100,000 PY","as_of":"2026-11-09","source":"Pharmacy Times"},{"claim":"Background NAION incidence adults >50","value":"2.3-10.2","unit":"per 100,000 per year","as_of":"2026-11-09","source":"Pharmacy Times"},{"claim":"EMA: NAION very rare with semaglutide","value":"up to 1 in 10,000","unit":"frequency","as_of":"2025-06-06","source":"EMA"},{"claim":"MHRA Yellow Card suspected NAION reports with semaglutide to 2025-08-01","value":3,"unit":"reports","as_of":"2026-02-05","source":"MHRA"},{"claim":"Semaglutide packs dispensed in UK over 5 years","value":10.2,"unit":"million","as_of":"2026-02-05","source":"MHRA"},{"claim":"FDA removed suicidal ideation warning (91 trials, 107,910 patients)","value":"2026-01-13","unit":"date","as_of":"2026-01-13","source":"FDA"},{"claim":"TFDA required NAION labeling for semaglutide products","value":"2026-06","unit":"date","as_of":"2026-11-10","source":"自由時報"},{"claim":"TFDA GLP-1 suspected ADR reports this year (39 for weight loss)","value":63,"unit":"reports","as_of":"2026-11-10","source":"自由時報"},{"claim":"Ozempic (胰妥讚) Taiwan sales rank 2025","value":10,"unit":"rank","as_of":"2026-04-07","source":"世界新聞網"},{"claim":"Mounjaro Q3 2026 revenue","value":10.723,"unit":"USD billion","as_of":"2026-10-29","source":"藥時事 2026-11-02 (Lilly Q3)"},{"claim":"Wegovy pill US prescriptions Q3 2026","value":3.6,"unit":"million","as_of":"2026-11-04","source":"TimesLIVE/Reuters"},{"claim":"Foundayo ATTAIN-OSA AHI reduction (no PAP) vs placebo -6.3%","value":-43.8,"unit":"%","as_of":"2026-11-09","source":"Eli Lilly"},{"claim":"SUSTAIN-6 retinopathy complications semaglutide vs placebo","value":"3.0% vs 1.8%","unit":"%","as_of":"2016-11-10","source":"NEJM"},{"claim":"GLP-1 NAION MDL","value":"3163","unit":"MDL No.","as_of":"2025-12-17","source":"Levin Papantonio"}],"sections":["01｜The \"1.7x risk\" rests on 15 cases","02｜FDA moved last, and went widest","03｜A boxed warning never slowed sales; this one won't either","04｜How the business changes: courts, eye clinics and Lilly's pill","05｜Taiwan: Wegovy's label is done, Mounjaro is waiting","06｜Where we could be wrong","References"],"references":[{"title":"FDA Requires Safety Labeling Changes for GLP-1 RAs Due to Potential Increased Risk of Rare But Serious Eye Condition","source":"U.S. FDA","date":"2026-11-09","url":"https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential"},{"title":"FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk","source":"Pharmacy Times","date":"2026-11-10","url":"https://www.pharmacytimes.com/view/fda-requires-class-wide-glp-1-ra-labeling-changes-for-potential-naion-risk"},{"title":"FDA warns GLP-1 may raise optic neuropathy risk; TFDA to re-evaluate","source":"Liberty Times","date":"2026-11-10","url":"https://news.ltn.com.tw/news/life/breakingnews/5636292"},{"title":"TFDA launches safety re-evaluation","source":"China Times","date":"2026-11-10","url":"https://www.chinatimes.com/realtimenews/20261110003523-260405"},{"title":"FDA orders warning on GLP-1s","source":"Commercial Times","date":"2026-11-11","url":"https://www.ctee.com.tw/news/20261111700138-439901"},{"title":"October - December 2024 Potential Signals of Serious Risks","source":"U.S. FDA","date":"2025-03-31","url":"https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2024-new-safety-information-or-potential-signals-serious-risks-identified-fda"},{"title":"PRAC concludes NAION is a very rare side effect of semaglutide","source":"EMA","date":"2025-06-06","url":"https://www.ema.europa.eu/pt/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy"},{"title":"The use of semaglutide medicines and risk of NAION","source":"WHO","date":"2025-06-27","url":"https://www.who.int/news/item/27-06-2025-27-06-2025-semaglutide-medicines-naion"},{"title":"Semaglutide: risk of NAION","source":"MHRA Drug Safety Update","date":"2026-02-05","url":"https://www.gov.uk/drug-safety-update/semaglutide-wegovy-ozempic-and-rybelsus-risk-of-non-arteritic-anterior-ischemic-optic-neuropathy-naion"},{"title":"FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 RAs","source":"U.S. FDA","date":"2026-01-13","url":"https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp"},{"title":"SUSTAIN-6","source":"New England Journal of Medicine","date":"2016-11-10","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1607141"},{"title":"Lilly's Foundayo significantly reduced obstructive sleep apnea severity","source":"Eli Lilly","date":"2026-11-09","url":"https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-orforglipron-significantly-reduced-obstructive"},{"title":"Novo Nordisk lifts 2026 outlook as Wegovy pill surges","source":"TimesLIVE / Reuters","date":"2026-11-04","url":"https://www.timeslive.co.za/news/world/2026-11-04-novo-nordisk-lifts-2026-outlook-as-wegovy-pill-surges/"},{"title":"Lilly Q3 2026: price down, volume up","source":"Drugnews","date":"2026-11-02","url":"https://drugnews.com.tw/articles/2026-11-02-lilly-q3-2026-glp1-price-cut-volume-novo.html"},{"title":"Federal court creates new MDL for GLP-1 vision loss","source":"Levin Papantonio (press release","date":"2025-12-17","url":"https://business.mammothtimes.com/mammothtimes/article/gnwcq-2025-12-17-levin-papantonio-federal-court-creates-new-mdl-for-ozempic-and-other-glp-1-drugs-linked-to-vision-loss-naion"},{"title":"Hundreds of lawsuits allege GLP-1s caused permanent vision loss","source":"WCAX / Gray News","date":"2026-09-22","url":"https://www.wcax.com/2026/09/22/hundreds-lawsuits-allege-glp-1s-like-ozempic-wegovy-mounjaro-caused-permanent-vision-loss/"},{"title":"GLP-1 Drugs Under Scrutiny as Lawsuits Allege NAION Risk","source":"Review of Optometry","date":"2026-09-22","url":"https://www.reviewofoptometry.com/article/glp1-drugs-under-scrutiny-as-lawsuits-allege-naion-risk"},{"title":"Taiwan's top 10 best-selling drugs","source":"World Journal","date":"2026-04-07","url":"https://www.worldjournal.com/wj/story/121221/9425242"}],"images":[{"alt":"Fig. 1｜The absolute numbers behind the ratio","url":"https://drugnews.com.tw/assets/articles/glp1-naion-vision-warning-fda-classwide-mounjaro-taiwan-en/figure-01.png"},{"alt":"Fig. 2｜Regulators moved on semaglutide first; FDA went class-wide","url":"https://drugnews.com.tw/assets/articles/glp1-naion-vision-warning-fda-classwide-mounjaro-taiwan-en/figure-02.png"},{"alt":"Fig. 3｜NAION: a stroke at the front of the optic nerve","url":"https://drugnews.com.tw/assets/articles/glp1-naion-vision-warning-fda-classwide-mounjaro-taiwan-en/figure-03.png"},{"alt":"Fig. 4｜Whose label already says it","url":"https://drugnews.com.tw/assets/articles/glp1-naion-vision-warning-fda-classwide-mounjaro-taiwan-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/glp1-naion-vision-warning-fda-classwide-mounjaro-taiwan-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-14）。FDA adds a vision-loss warning to every GLP-1。https://drugnews.com.tw/articles/2026-11-14-glp1-naion-vision-warning-fda-classwide-mounjaro-taiwan-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"What are the key developments in “On November 9, 2026, FDA required all GLP-1 drugs to add NAION to the Warnings and Precautions section, covering semaglutide, tirzepatide and oral orforglipron”?","a":"On November 9, 2026, FDA required all GLP-1 drugs to add NAION to the Warnings and Precautions section, covering semaglutide, tirzepatide and oral orforglipron."},{"q":"What are the key developments in “FDA's 126-trial meta-analysis found 15 probable cases, 6.4 versus 3.8 per 100,000 person-years”?","a":"FDA's 126-trial meta-analysis found 15 probable cases, 6.4 versus 3.8 per 100,000 person-years; versus SGLT-2 inhibitors in real-world data the hazard ratio was 1.19, not significant."},{"q":"What are the key developments in “Taiwan's FDA required NAION labeling only for semaglutide in June 2026 and announced a class-wide safety re-evaluation on November 10”?","a":"Taiwan's FDA required NAION labeling only for semaglutide in June 2026 and announced a class-wide safety re-evaluation on November 10."}]}